CRCT News
IMLINFO / Cross-border Network of Personalized Immunotherapies for Non-Hodgkin’s Lymphomas
IMLINFO is a cross-border network of personalized immunotherapies for Non-Hodgkin's lymphomas (NHL) involving 7 organizations located in Spain and France. Its main objective is to determine the efficacy of new immunotherapy treatments through the creation of a NHL...
read more
Publication team 2 (J.S. Hoffmann) / ARTEMIS and XPF-ERCC1: 2 nucleases to prevent genetic instability
Bétous, R., Goullet de Rugy, T., Pelegrini, A.L., Queille, S., de Villartay, J.-P., & Hoffmann, J.-S.*, 2018. DNA replication stress triggers Rapid DNA Replication Fork Breakage by Artemis and XPF. PLoS Genet. 14, e1007541. DNA replication stress (DRS) leads to...
read more
Focus: collaboration between Pierre Cordelier’s team & Neovirtech on oncolitic viruses
Discover in this France 3 TV report the collaboration between the CRCT team led by Dr. Pierre Cordelier and the Toulouse start-up Neovirtech: a therapeutic innovation opening up new perspectives in the treatment of cancer. [video width="960" height="540"...
read more
Focus: IMMUSPHINX program – Targeting sphingolipid metabolism to improve the efficacy of immunotherapies in melanoma
Thanks to anticancer immunotherapies targeting immune checkpoints, the proportion of patients with metastatic melanoma (MM) in remission after 5 years has tripled during the last years. However, therapeutic options are sparse for patients who do not respond to...
read more
Open position: post-doctoral fellow (team 13)
Profile We seek a highly motivated scientist that hold a Ph.D in immunology with a strong background in cellular immunology, cell signaling and experience in mouse models. Good track record, communication, technical and organizational skills are expected. Offer The...
read more
New publication in Nature Communications !
Dendrogenin A drives LXR to trigger lethal autophagy in cancers Dendrogenin A, a metabolite of cholesterol, has tumor suppressive properties but the mechanisms of action were until know unknown. In this collaborative work between team 12 of the CRCT (Marc &...
read more